Imidazoline Receptors

Receptors of CLONIDINE and other IMIDAZOLINES. Activity of the ligands was earlier attributed to ADRENERGIC ALPHA-2 RECEPTORS. Endogenous ligands include AGMATINE, imidazoleacetic acid ribotide, and harman.

Also Known As:

Imidazoline Guanidinium Receptor; Imidazoline Guanidinium Receptors; Receptor, Imidazoline; Receptor, Imidazoline-Guanidinium; Receptors, Imidazoline; Receptors, Imidazoline Guanidinium; Imidazoline Receptor; Imidazoline-Guanidinium Receptor; Imidazoline-Guanidinium Receptors; Receptors, Imidazoline-Guanidinium

Networked: 122 relevant articles (8 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Drug Receptors: 61
    - Imidazoline Receptors: 122

Experts

1.	Zheng, Rong-Yuan: 4 articles (03/2015 - 05/2006)
2.	Bousquet, Pascal: 3 articles (01/2020 - 01/2017)
3.	Nikolic, Katarina: 3 articles (01/2020 - 02/2015)
4.	Vucicevic, Jelica: 3 articles (01/2020 - 02/2015)
5.	Chopde, Chandrabhan T: 3 articles (01/2019 - 09/2009)
6.	Kotagale, Nandkishor R: 3 articles (01/2019 - 09/2009)
7.	Taksande, Brijesh G: 3 articles (01/2019 - 09/2009)
8.	Han, Zhao: 3 articles (11/2018 - 03/2011)
9.	Hou, Sheng-Tao: 3 articles (03/2015 - 03/2011)
10.	Burke, S L: 3 articles (01/2005 - 06/2000)

Related Diseases

1.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/04/2011 - "Our previous studies showed that ligands to type 2 imidazoline receptors (I(2)R) were effective in protecting spinal cord injury caused by experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. In this study, we further examined the protective property of a very selective ligand of I(2)R, 2-(2-benzofuranyl) 2-imidazoline (2-BFI) against EAE. " 03/01/2015 - "Our previous studies showed that 2-(2-benzofuranyl)-2-imidazoline (2-BFI), a ligand to type 2 imidazoline receptor, was protective against brain and spinal cord injury caused by experimental autoimmune encephalomyelitis (EAE). " 11/05/2012 - "Our previous studies showed that ligands to type 2 imidazoline receptors (I₂R), including 2-(2-Benzofuranyl)-2-imidazoline (2-BFI) and Idazoxan, were effective in reducing spinal cord inflammation caused by experimental autoimmune encephalomyelitis (EAE). "
2.	Spinal Cord Injuries (Spinal Cord Injury) 03/04/2011 - "Our previous studies showed that ligands to type 2 imidazoline receptors (I(2)R) were effective in protecting spinal cord injury caused by experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. In this study, we further examined the protective property of a very selective ligand of I(2)R, 2-(2-benzofuranyl) 2-imidazoline (2-BFI) against EAE. " 03/01/2015 - "Our previous studies showed that 2-(2-benzofuranyl)-2-imidazoline (2-BFI), a ligand to type 2 imidazoline receptor, was protective against brain and spinal cord injury caused by experimental autoimmune encephalomyelitis (EAE). "
3.	Essential Hypertension 01/01/1998 - "[Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension]." 11/01/2001 - "Pharmacologic sympathetic nervous suppression within the central nervous system with imidazoline receptor-binding agents such as rilmenidine is a logical therapeutic approach for lowering blood pressure (BP) in patients with essential hypertension, in whom sympathetic activity is often increased. " 05/01/1997 - "The manufacturer claims that moxonidine "accurately targets imidazoline receptors at the cardiovascular control centre in the brainstem" and is "as effective as current first-line therapies for essential hypertension". " 12/01/2001 - "[Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. "
4.	Hypertension (High Blood Pressure) 01/01/2022 - "The study included data on the sales of Imidazoline Receptor Agonists in Lithuania, Latvia, and Estonia; the marketing authorization databases of the competent authorities; the guidelines on the treatment of hypertension, and the reimbursement conditions. " 04/15/2021 - "To compare the strategies for hypertension management and features of clinical use of I1-imidazoline receptor (I1-IR) agonists in the Russian Federation and other countries where the STRAIGHT (Selective imidazoline receptor agonists Treatment Recommendation and Action In Global management of HyperTension) study was conducted. " 04/15/2021 - "Сравнение терапевтической тактики при лечении АГ и особенностей клинического использования селективных агонистов I1-имидазолиновых рецепторов (АИР) в Российской Федерации по сравнению с другими странами-участниками международного исследования STRAIGHT (Selective imidazoline receptor agonists Treatment Recommendation and Action In Global management of HyperTension). " 12/01/2020 - "The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT)." 01/01/2003 - "Recently imidazoline receptor agonists have been used in the treatment of hypertension. "
5.	Pain (Aches) 09/01/2015 - "In this respect, the involvement of the imidazoline receptors in pain modulation has drawn attention in recent years. " 09/01/2015 - "This educational forum exhibits the role of imidazoline receptors and ligands in pain process by utilizing experimental studies. " 09/01/2015 - "Thus, the use of the ligands which bind to the imidazoline receptors is an effective strategy for relieving pain. " 09/01/2015 - "In this review, it is aimed to focus on the imidazoline receptors and their ligands which contribute to the pain modulation. " 09/01/2015 - "The imidazoline receptors and ligands in pain modulation."

Related Drugs and Biologics

1.	Ligands
2.	moxonidine (Moxon)
3.	2-(2-benzofuranyl)-2-imidazoline
4.	Idazoxan
5.	2-imidazoline
6.	Rilmenidine (Hyperium)
7.	Agmatine
8.	Adrenergic Receptors (Adrenergic Receptor)
9.	Adrenergic Agents (Adrenergic Drugs)
10.	Clonidine (ST 155)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Intravenous Administration
4.	Controlled Hypotension
5.	Drug Therapy (Chemotherapy)